公开(公告)号：US20190315687A1

公开(公告)日：2019-10-17

申请号：US16442023

申请日：2019-06-14

Applicant: AbbVie S.à.r.l. ,  Galapagos NV

Inventor： Robert J. Altenbach ,  Andrew Bogdan ,  Nicolas Desroy ,  Gregory A. Gfesser ,  Stephen N. Greszler ,  John R. Koenig ,  Philip R. Kym ,  Bo Liu ,  Marc J. Scanio ,  Xenia B. Searle ,  Xueqing Wang ,  Ming C. Yeung ,  Gang Zhao

IPC: C07D207/16 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/506 ,  A61K45/06 ,  A61K31/40 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14

Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

公开(公告)号：US10130622B2

公开(公告)日：2018-11-20

申请号：US15288400

申请日：2016-10-07

Applicant: AbbVie S.à.r.l. ,  Galapagos NV

Inventor： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Katja E. Conrath ,  Douglas Cyr ,  Elsa De Lemos ,  Gert Jules Hector De Wilde ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Mathieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Chris Tse ,  Steven Emiel Van der Plas ,  Xueqing Wang

IPC: A61K31/437 ,  A61K31/4545 ,  C07D471/04 ,  C07D519/00 ,  A61K45/06 ,  G01N33/50

Abstract: A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.

公开(公告)号：US20180099931A1

公开(公告)日：2018-04-12

申请号：US15726075

申请日：2017-10-05

Applicant: AbbVie S.à.r.l. ,  Galapagos NV

Inventor： Robert J. Altenbach ,  Andrew Bogdan ,  Sylvain Couty ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Stephen N. Greszler ,  Christopher Gaëtan Housseman ,  John R. Koenig ,  Philip R. Kym ,  Bo Liu ,  Marc J. Scanio ,  Xenia Searle ,  Xueqing Wang ,  Ming C. Yeung ,  Gang Zhao

IPC: C07D207/14 ,  C07D207/48

CPC classification number: C07D207/14 ,  A61P11/00 ,  C07D207/48 ,  C07D401/04 ,  C07D401/14 ,  C07D405/06

Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

公开(公告)号：US20170190693A1

公开(公告)日：2017-07-06

申请号：US15467737

申请日：2017-03-23

Applicant: AbbVie S.à.r.l. ,  Galapagos NV

Inventor： Robert J. Altenbach ,  Andrew Bogdan ,  Stephen N. Greszler ,  John R. Koenig ,  Philip R. Kym ,  Bo Liu ,  Xenia B. Searle ,  Eric Voight ,  Xueqing Wang ,  Ming C. Yeung

IPC: C07D407/12

Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20170101405A1

公开(公告)日：2017-04-13

申请号：US15287911

申请日：2016-10-07

Applicant: AbbVie S.à.r.l ,  Galapagos NV

Inventor： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Brian S. Brown ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Nuria Merayo Merayo ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V. Patel ,  Matthieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Steven Em iel Van der Plas ,  Xueqing Wang ,  Ann de Blieck

IPC: C07D471/04 ,  A61K31/4545 ,  A61K31/437 ,  A61K31/506 ,  A61K45/06 ,  A61K31/5377

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D519/00 ,  A61K2300/00

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20190127356A1

公开(公告)日：2019-05-02

申请号：US16225991

申请日：2018-12-19

Applicant: AbbVie S.à.r.l. ,  Galapagos NV

Inventor： Robert J. Altenbach ,  Andrew Bogdan ,  Stephen N. Greszler ,  John R. Koenig ,  Philip R. Kym ,  Bo Liu ,  Xenia B. Searle ,  Eric Voight ,  Xueqing Wang ,  Ming C. Yeung

IPC: C07D407/12 ,  C07D491/107 ,  C07D491/052 ,  A61K31/5377 ,  A61K31/453 ,  A61K31/4433 ,  A61K31/435 ,  A61K45/06 ,  A61K31/397 ,  A61K31/353 ,  A61K31/00 ,  A61K31/436 ,  C07D413/14 ,  C07D405/14 ,  A61K31/4025

Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US10118916B2

公开(公告)日：2018-11-06

申请号：US15496094

申请日：2017-04-25

Applicant: AbbVie S.à.r.l. ,  Galapagos NV

Inventor： Robert J. Altenbach ,  Andrew Bogdan ,  Vincent Chan ,  Timothy A. Grieme ,  John R. Koenig ,  Philip R. Kym ,  Bo Liu ,  Karine Fabienne Malagu ,  Sachin V. Patel ,  Marc Scanio ,  Xenia B. Searle ,  Shashank Shekhar ,  Xueqing Wang ,  Ming C. Yeung

IPC: C07D407/12 ,  A61K31/36 ,  C07D311/68 ,  A61K31/353 ,  C07D311/70 ,  A61K31/352 ,  C07D311/58 ,  C07D311/60 ,  C07D407/14

Abstract: The present invention provides for compounds of formula (I) wherein R1, m, Z, G1, R2, and R3 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20180244640A1

公开(公告)日：2018-08-30

申请号：US15902802

申请日：2018-02-22

Applicant: AbbVie S.à.r.l. ,  Galapagos NV

Inventor： Robert J. Altenbach ,  Andrew Bogdan ,  Nicolas Desroy ,  Gregory A. Gfesser ,  Stephen N. Greszler ,  Philip R. Kym ,  Bo Liu ,  Karine Fabienne Malagu ,  Nuria Merayo Merayo ,  Mathieu Rafaël Pizzonero ,  Xenia B. Searle ,  Steven Emiel Van der Plas ,  Xueqing Wang ,  Ming C. Yeung ,  Gang Zhao

IPC: C07D311/04 ,  C07D311/76 ,  C07D307/81 ,  A61P11/00

CPC classification number: C07C311/51 ,  A61P11/00 ,  C07C317/14 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/06 ,  C07C2602/08 ,  C07C2602/10 ,  C07D215/48 ,  C07D307/16 ,  C07D307/81 ,  C07D311/04 ,  C07D311/76 ,  C07D317/68 ,  C07D319/22 ,  C07D405/12 ,  C07D407/12

Abstract: The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

公开(公告)号：US09840513B2

公开(公告)日：2017-12-12

申请号：US15205512

申请日：2016-07-08

Applicant: AbbVie S.à.r.l. ,  Galapagos NV

Inventor： Robert J. Altenbach ,  Andrew Bogdan ,  Marlon D. Cowart ,  William Ramesh Esmieu ,  Gregory A. Gfesser ,  Stephen N. Greszler ,  John R. Koenig ,  Philip R. Kym ,  Bo Liu ,  Karine Fabienne Malagu ,  Sachin V. Patel ,  Marc J. Scanio ,  Xenia B. Searle ,  Eric Voight ,  Xeuquing Wang ,  Ming C. Yeung

IPC: C07D493/04 ,  C07D317/70 ,  C07D405/12 ,  C07D407/12 ,  C07D519/00 ,  A61K31/357 ,  A61K31/397 ,  A61K31/433 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/5377 ,  A61K45/06

CPC classification number: C07D493/04 ,  A61K31/357 ,  A61K31/397 ,  A61K31/433 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/5377 ,  A61K45/06 ,  C07D317/70 ,  C07D405/12 ,  C07D407/12 ,  C07D519/00

Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20170101406A1

公开(公告)日：2017-04-13

申请号：US15287922

申请日：2016-10-07

Applicant: AbbVie S.à.r.l. ,  Galapagos NV

Inventor： Rhalid Akkari ,  Luke Jonathan Alvey ,  Xavier Marie Bock ,  Pieter Isabelle Roger Claes ,  Marlon D. Cowart ,  Elsa De Lemos ,  Nicolas Desroy ,  Béranger Duthion ,  Gregory A. Gfesser ,  Romain Luc Marie Gosmini ,  Christopher Gaëtan Housseman ,  Koen Karel Jansen ,  Jianguo Ji ,  Philip R. Kym ,  Jean-Michel Lefrancois ,  Oscar Mammoliti ,  Christel Jeanne Marie Menet ,  Gregory John Robert Newsome ,  Adeline Marie Elise Palisse ,  Sachin V Patel ,  Mathieu Rafaël Pizzonero ,  Anurupa Shrestha ,  Elizabeth C. Swift ,  Steven Emiel Van der Plas ,  Xueqing Wang

IPC: C07D471/04 ,  A61K31/5377 ,  C07D519/00 ,  A61K31/496 ,  A61K31/541 ,  A61K31/506 ,  A61K45/06 ,  A61K31/437

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07D519/00 ,  A61K2300/00

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).